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Mucormycosis is the second most common cause of invasive mould infection and causes disease in
diverse hosts, including those who are immuno-competent. We conducted a multicentre retrospective
study of proven and probable cases of mucormycosis diagnosed between 2004e2012 to determine the
epidemiology and outcome determinants in Australia. Seventy-four cases were identified (63 proven, 11
probable). The majority (54.1%) were caused by Rhizopus spp. Patients who sustained trauma were more
likely to have non-Rhizopus infections relative to patients without trauma (OR 9.0, p 0.001, 95% CI 2.1
e42.8). Haematological malignancy (48.6%), chemotherapy (42.9%), corticosteroids (52.7%), diabetes
mellitus (27%) and trauma (22.9%) were the most common co-morbidities or risk factors. Rheumato-
logical/autoimmune disorders occurred in nine (12.1%) instances. Eight (10.8%) cases had no underlying
co-morbidity and were more likely to have associated trauma (7/8; 87.5% versus 10/66; 15.2%; p <0.001).
Disseminated infection was common (39.2%). Apophysomyces spp. and Saksenaea spp. caused infection in
immuno-competent hosts, most frequently associated with trauma and affected sites other than lung
and sinuses. The 180-day mortality was 56.7%. The strongest predictors of mortality wereof Infectious Diseases and Microbiology, Canberra Hospital & Health Services, PO Box 11, Woden ACT 2606, Australia
ennedy).
biology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.




zygomycosisrheumatological/autoimmune disorder (OR ¼ 24.0, p 0.038 95% CI 1.2e481.4), haematological malig-
nancy (OR ¼ 7.7, p 0.001, 95% CI 2.3e25.2) and admission to intensive care unit (OR ¼ 4.2, p 0.02, 95% CI
1.3e13.8). Most deaths occurred within one month. Thereafter we observed divergence in survival be-
tween the haematological and non-haematological populations (p 0.006). The mortality of mucormycosis
remains particularly high in the immuno-compromised host. Underlying rheumatological/autoimmune
disorders are a previously under-appreciated risk for infection and poor outcome. K.J. Kennedy, CMI
2016;22:775
© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Infections caused by fungi of the order Mucorales are uncom-
mon, but are significant for their aggressive nature, challenges in
diagnosis and high mortality (40e100%) despite antifungal and
surgical therapy [1e6]. The Mucorales are a diverse group of fungi
associated with characteristic presentations according to underly-
ing host conditions [1e3]. A significant proportion of infection also
occurs in hosts with no apparent immune compromise, often in
association with trauma [1e3,7,8].
The epidemiology of mucormycosis may be changing with the
emergence of uncommon genera such as Apophysomyces [7,9],
increasing numbers and breadth of immuno-compromised hosts
[1] and outbreaks of infection following natural disasters and iat-
rogenic or other environmental exposure [7,10,11]. However,
despite reports of rising incidence of mucormycosis [1,4,12], data on
infection risks, treatment and outcomes are limited to case series
and expert opinion. The epidemiology of mucormycosis varies be-
tween geographic regions [1e5,9,12], so knowledge of local pat-
terns of disease is necessary to inform diagnosis and management.
This multicentre study provides contemporary insights into the
epidemiology, predisposing factors and determinants of outcomes
of mucormycosis in Australia.Materials and Methods
Study design
A retrospective multicentre, observational study of mucor-
mycosis in adults was conducted across 15 Australian tertiary
hospitals from 2004 to 2012 under the auspices of the Australia
and New Zealand Mycoses Interest Group, and formed a sub-
study of a recently published analysis of invasive fungal dis-
ease (IFD) caused by non-Aspergillus moulds [13]. Institutional
Human Research Ethics Committees approval was obtained at
each site.Collection of data
Cases were identified through a combination of pathology lab-
oratory information systems, infectious diseases databases and
hospital medical records coding [14]. A data review committee
assessed each case for study inclusion. Only proven or probable
infections were included. Patient demographics; co-morbid con-
ditions (e.g. malignancy); predisposing factors for mucormycosis
within the preceding 30 days of diagnosis (e.g. immunosuppressive
therapies, trauma); site(s) of infection; microbiological and histo-
logical results; antifungal and other therapies; and clinical outcome
at 30 and 180 days were collected.Definitions
Proven or probable cases of mucormycosis were defined based
on the European Organization for Research and Treatment of
Cancer/Mycoses Study Group (EORTC/MSG) definitions for IFD [15].
However, in contrast to the EORTC/MSG criteria for assignment of
probable IFD, host-specific criteria were not required.
Disseminated infection involved two or more non-contiguous
sites or positive blood cultures. Gastrointestinal (GI) tissue in-
fections included the intestinal tract, pancreas and liver. Prior
antifungal use was defined as >7 days of treatment within the
previous 30 days. Clinical outcome was assessed as all-cause mor-
tality at 30 and 180 days.Histopathological and microbiological examination
Clinical specimens were examined by experienced histopa-
thologists at participating sites using local institutional protocols.
The identity of cultured Mucorales was performed using standard
phenotypic methods and, where available, characterized at a
reference laboratory (Westmead Hospital or SA Pathology) by DNA
sequencing targeting the internal transcribed spacer (ITS) regions
or the D1/D2 regions of the 28S rRNA gene [16,17]. In some cases,
panfungal PCR targeting the ITS 1 region was performed to identify
Mucorales in histopathological specimens [18]. If species identifi-
cation was not possible either by culture or by molecular methods,
isolates were categorised either by genus or as ‘unclassified
Mucorales’.Statistical analysis
Cases of ‘unclassified Mucorales’ were excluded when com-
parisons were made between genera. Categorical variables were
compared using the c2 or Fishers exact test, and continuous
variables by the Student's t test or Mann-Whitney U test where
appropriate. Determinants of all-cause 30-day and 180-day
mortality were examined by univariate and multivariate anal-
ysis. Backward, stepwise multivariate analysis was conducted
with Firth's penalized-likelihood logistic regression due to the
presence of complete separation of one variable. Variables with a
univariate p value <0.20 were considered for inclusion in the
model for multivariate analysis. Variables with p values 0.05 in
a significant model with the largest penalized log likelihood were
included within the final model. KaplaneMeier survival analysis
was performed for all-cause 180-day mortality and assessed by
the log rank test. Calculations were computed using STATA (Sta-
taCorp. 2015. STATA Statistical Software: Release 14. College
Station, TX).
Fig. 1. Distribution of mucormycosis cases according to age and fungal genera.
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Seventy-four Mucorales infections were identified including 63
(85%) proven and 11 (15%) probable cases. There were no clusters of
infection, with cases evenly distributed across the study period. The
median patient age was 54 years (interquartile range (IQR)
42e63 years), and 48 (65%) of patients male. Although the number
of cases varied across age groups, fungal aetiology was similar
(Fig. 1). Thirty-three patients (45%) were admitted to an intensive
care unit (ICU) at the time of diagnosis because of the fungal
infection and/or underlying condition.
Diagnosis and aetiological agents
Seventeen cases (23%) of mucormycosis were diagnosed by
histopathology without a positive culture. Twenty-five cases (34%)Table 1









Apophysomyces elegans 3 2




Mucor spp. 7 (9.5%)
Mucor circinelloides 1 1
Mucor indicus 1 1
Mucor spp. 5 3
Rhizomucor spp. 5 (6.8%)
Rhizomucor miehei 1 1
Rhizomucor pusillus 1 1
Rhizomucor spp. 3 2
Rhizopus spp. 40 (54.1%)
Rhizopus microsporus 12 7
Rhizopus arrhizus 10 4
Rhizopus schipperae 1 1
Rhizopus stolonifer 2 2









a Characteristic hyphae of Mucorales seen on histopathology without identifica-
tion by culture or DNA sequencing.
b DNA sequencing either (i) corroborated the species identification provided by
phenotypic methods or (ii) provided genus-level and/or species-level identification
where morphological methods failed to provide an identification.were diagnosed by culture without histopathology, and 32 cases
(43%) were diagnosed by both culture and histopathology.
Molecular methods provided identification or confirmation of
fungal identity to genus (n ¼ 9) or species (n ¼ 26) level in 35 (47%)
cases (Table 1), including five cases diagnosed by histopathology
without culture.
A broad range of pathogens were identified, with Rhizopus spp.
accounting for the majority (Table 1). Saksenaea vasiformis complex
and Apophysomyces species contributed over 10% of cases. One
patient had infection with Mucor circinelloides (lung) and Fusarium
spp. (blood and skin) resulting in death. No other mixed infections
were identified.
Co-morbidity and predisposing factors
The commonest co-morbidities were haematological malig-
nancy (48.6%) and diabetes mellitus (27%), although; none with
ketoacidosis (Table 2). Rheumatological/autoimmune diseases
were present in 9 (12.1%) cases (rheumatoid arthritis (n ¼ 2), sys-
temic lupus erythematosus (3), vasculitis (2), autoimmune hepa-
titis (1) and autoimmune haemolytic anaemia (1)). All but one of
these patients had received prior treatment with corticosteroids,
with combinations of other immunosuppressive drugs, including
rituximab (n¼ 1), infliximab (1), calcineurin inhibitor (1) and other
chemotherapeutic agents (3). Seventeen patients (22.9%) had
antecedent trauma, including motor vehicle accidents and burns,
with one patient sustaining massive injuries from the Boxing Day
tsunami in Asia. Eight patients (10.8%) had neither underlying co-
morbidity nor immuno-compromise, and were significantly more
likely to have acquired infection through trauma (7/8; 87.5%)
compared to trauma-related infections in those with an underlying
co-morbidity and/or immune-compromise (10/66; 15.2%;
p<0.001).
Patients who sustained trauma were significantly more likely to
have non-Rhizopus infections compared with patients without
trauma (11/15, 73.3% versus 11/47, 23.4%; OR 9.0; 95% CI 2.1e42.8; p
0.001).
Site of infection
The lung was the most common site of infection (44.6%), fol-
lowed by sinuses (29.7%), skin and soft tissue (20.3%), brain (14.9%)
and bone/joint (14.9%) (Table 3). Twenty-nine (39.2%) cases were
disseminated, with individual sites represented in various combi-
nations, including the lung (n ¼ 16), sinus (10), brain (9) and skin
(9). One patient had 4 sites and 6 patients 3 sites involved. All ep-
isodes of GI mucormycosis were disseminated. Of the patients with
rheumatological/autoimmune diseases, the lung (n ¼ 5), sinus (4),
brain (3), eye (1), skin (1) and heart (1) represented the sites of
infection, including 3 cases of disseminated disease.
Patient management
Antifungal treatment for mucormycosis was initiated in 64 pa-
tients (86.5%) and continued for a median of 64.5 days (IQR
21e365 days). Of those who survived 180 days (n¼ 33), the median
treatment duration was 196 days (IQR 64e587 days).
Eight patients either died before diagnosis or were actively
palliated without receiving antifungal therapy. Another patient
received voriconazole alone and died of disseminated infection at
17 days. One patient had trauma-related soft-tissue infection,
without underlying co-morbidity, was treated with surgery alone
and was alive at 180 days.
An amphotericin B formulation (predominantly liposomal
amphotericin B) was the mainstay of antifungal therapy (62/64
Table 2


















Noneb 8 (10.8) 0 2c (5) 1 (14.3) 1 (20) 2 (50) 2 (50) 0
Diabetes mellitus 20 (27.0) 4 (33.3) 13 (32.5) 0 0 1 (25) 2 (50) 0
Chronic lung disease 11 (14.9) 4 (33.3) 3 (7.5) 1 (14.3) 1 (20) 1 (25) 0 1 (50)
Haematological malignancyd 36 (48.6) 5 (41.7) 20 (50) 6 (89.6) 4 (80) 0 0 1 (50)
Solid organ cancer 2 (2.7) 1 (8.3) 0 1 (14.3) 0 0 0 0
Bone marrow transplant 13 (17.6) 0 9 (22.5) 4 (57.1) 0 0 0 0
Solid organ transplant 8 (10.8) 1 (8.3) 6 (15) 0 0 0 0 1 (50)
Rheumatological /
autoimmune conditions
9 (12.1) 2 (16.7) 4 (10) 1 (14.3) 2 (40) 0 0 0
Chronic renal failure 7 (9.5) 2 (16.7) 5 (12.5) 5 (71.4) 0 0 0 0
Predisposing factor
Neutropenia 32 (43.2) 4 (33.3) 17 (42.5) 6 (85.7) 4 (80) 0 0 1 (50)
Corticosteroid use 39 (52.7) 3 (25) 25 (62.5) 6 (85.7) 4 (80) 0 0 1 (50)
Cancer chemotherapy 31 (41.9) 4 (33.3) 18 (45) 5 (71.4) 3 (60) 0 0 1 (50)
Calcineurin inhibitors 15 (20.2) 0 14 (35) 1 (14.3) 0 0 0 0
Monoclonal antibodies 7 (9.5) 2 (16.7) 4 (10) 1 (14.3) 0 0 0 0
Major or minor trauma 17 (22.9) 2 (16.7) 4 (10) 3 (42.9) 2 (40) 3 (75) 3 (75) 0
Major surgery 18 (24.3) 2 (16.7) 9 (22.5) 0 1 (20) 1 (25) 3 (75) 2 (100)
Hospital construction 10 (13.5) 3 (25) 4 (10) 1 (14.3) 2 (40) 0 0 0
Antifungal prophylaxis Medicatione,f
Any agent 34 (44.9) 5 (41.7) 19 (45.7) 6 (85.7) 3 (60) 0 0 1 (50)
Voriconazole 10 (13.5) 1 (8.3) 6 (15) 1 (14.3) 2 (40) 0 0 0
Posaconazole 10 (13.5) 2 (16.7) 6 (15) 2 (28.6) 0 0 0 0
a Expressed as number of patients (percentage of patients with co-morbidity or predisposing factor).
b Also no host immuno-compromise.
c Rhizopus microsporus (n ¼ 1); Rhizopus schippelae (n ¼ 1).
d Haematological cancers included: acute leukaemia (n ¼ 16), chronic leukaemia (n ¼ 7), lymphoma (n ¼ 5), multiple myeloma (n ¼ 3), myelodysplastic syndrome (n ¼ 4)
and other cancers (n ¼ 2).
e Antifungal medications prescribed for at least 7 days within the preceding 30 days.
f Includes itraconazole (3), liposomal amphotericin B (1) and fluconazole (10).
Table 3
Mucormycosis: site of infection and 180-day mortality according to pathogen groupa


















Lung (n¼33) 4 20 5 3 0 0 1 24 (72.7%)
Sinus (n¼22) 5 13 2 1 0 0 1 14 (63.6%)
Skin/deep soft tissue (n¼15) 3 5 1 2 2 2 0 7 (46.7%)
Brain (n¼11) 1 5 0 1 1 1 2 9 (81.8%)
Bone/joint (n¼11) 2 5 0 0 2 2 0 3 (27.3%)
Gastrointestinal tissue (n¼7) 1 1 3 0 1 0 1 5 (71.4%)
Eye (n¼4) 2 1 0 0 0 1 0 1 (25%)
Blood (n¼2) 0 0 2 0 0 0 0 1 (50%)
Other (n¼7)b 0 4 1 1 0 0 1 4 (57.1%)
Disseminated (n¼29) 5 12 5 1 3 1 2 18 (62.1%)
180-day mortality
(n¼42; 57%)
5 (41.7%) 23 (57.5%) 6 (85.7%) 3 (60%) 2 (50%) 1 (25%) 2 (100%)
a Numbers total more than 74 as many patients had more than one site of infection.
b Includes kidney (n ¼ 3); endocardium (n ¼ 1); gingival tissue (n ¼ 1); genitalia (n ¼ 1).
K.J. Kennedy et al. / Clinical Microbiology and Infection 22 (2016) 775e781778cases), with amphotericin B-based combination therapy admin-
istered in 11 cases (17.7%), including caspofungin (n ¼ 5), pos-
aconazole (n ¼ 5) and terbinafine (n ¼ 1). Posaconazole alone, or
in combination with caspofungin, was used as definitive therapy
in two patients. Posaconazole solution was used as step-down
therapy in all cases where the patient was alive following initial
‘induction antifungal therapy’. Adjunctive gran-
ulocyteemacrophage colony-stimulating factor or granulocyte
infusion therapies were administered to two acute myeloid
leukaemia patients with fatal lung (þ/ sinus) infection. Surgery
was performed in 44 of 64 (69%) patients receiving anti-fungal
therapy.Outcomes
The all-cause 30- and 180-day mortality was 42% (n ¼ 31) and
56.7% [42] respectively. Deaths occurred at amedian of 14 days (IQR
4e32 days, range 1e169 days) following diagnosis.
Table 4 demonstrates the variables associated with mortality at
180 days by univariate and multivariate analyses. Independent
predictors of mortality on multivariate analysis were the presence
of a rheumatological/autoimmune disorder (OR ¼ 24.0, p 0.038,
95% CI 1.2e481.4), haematological malignancy (OR ¼ 7.7, p 0.001,
95% CI 2.3e25.2) and ICU admission (OR ¼ 4.2, p 0.02, 95% CI
1.3e13.8). The KaplaneMeier survival curves for the whole patient
Table 4
Mucormycosis: univariate and multivariate analysis of overall 180-day mortality
Variable Univariate analysis Multivariate analysis
Died (n¼42) Alive (n¼32) p value OR (95% CI) p value OR (95% CI)
Male gender (n¼48) 26 (62%) 22 (69%) 0.54 e e e
Co-morbidities / Predisposing conditions
Diabetes (n¼20) 10 (24%) 10 (31%) 0.41 e e e
Chronic lung disease (n¼11) 6 (14%) 5 (16%) 0.87 e e e
Chronic renal failure (n¼7) 3 (7%) 4 (13%) 0.46 e e e
Rheumatological/ autoimmune disorders (n¼9) 9 (22%) 0 (0%) 0.004 ea 0.038 24.0 (1.2e481.4) a
Haematological malignancy (n¼36) 27 (64%) 9 (28%) 0.002 4.6 (1.7e12.3) 0.001 7.7 (2.3e25.2)
Bone marrow transplant (n¼13) 10 (24%) 3 (9%) 0.132 e e e
Solid organ transplant (n¼8) 4 (10%) 4 (13%) 0.69 e e e
No co-morbidities (n¼8) 1 (2%) 7 (22%) 0.02 0.087 (0e0.59) e NS
Additional predisposing factors within the preceding 30 days
Major/minor trauma (n¼17) 7 (17%) 10 (31%) 0.11b e e NS
Surgery (n¼18) 10 (24%) 8 (25%) 0.9 e e e
ICU admission (n¼33) 23 (55%) 10 (31%) 0.044 8.1 (2.9e23) 0.020 4.2 (1.3e13.8)
Hospital construction (n¼10) 4 (10%) 6 (19%) 0.31 e e e
Cancer chemotherapy (n¼31) 23 (55%) 8 (25%) 0.01 7.67 (2.56e23) e NS
Corticosteroids (n¼39) 29 (69%) 10 (31%) 0.001 4.9 (1.8e13.1) e NS
Monoclonal antibodies (n¼7) 6 (14%) 1 (3%) 0.13b e e NS
Calcineurin inhibitors (n¼15) 8 (19%) 7 (22%) 0.77 e e e
Neutropenia (n¼32) 25 (60%) 7 (22%) 0.001 5.25 (1.89e14.6) e NS
Manifestations of infection
Disseminated infection (n¼29) 18 (43%) 11 (34%) 0.46 e e e
Antifungal treatments
Surgery (n¼45) 20 (51%) 25 (78%) 0.02 0.29 (0.11e0.83) e NS
Amphotericin B combination antifungal therapy (n¼11) 6 (14%) 5 (16%) 0.87 e e e
Combination surgery and antifungal agent (n¼44) 20 (48%) 24 (75%) 0.02 0.25 (0.09e0.71) e NS
a Rheumatological/autoimmune disorders is a perfect predictor of mortality and therefore OR, 95% CI and p values cannot be determined in the univariate analysis. Firth's
logistic regression was used for multivariate calculations.
b Variables that were included in the multivariate analysis and remained in the final model but where p >0.05 on univariate analysis.
Fig. 2. (a) KaplaneMeier survival curve of all patients with mucormycosis. (b)
KaplaneMeier survival curve stratified by the presence or absence of haematological
malignancy (p 0.006).
K.J. Kennedy et al. / Clinical Microbiology and Infection 22 (2016) 775e781 779cohort (Fig. 2a) and stratified by the presence of haematological
malignancy (Fig. 2b), demonstrate that most deaths occurred
within the first month, with subsequent divergence in survival
between the haematological and non-haematological populations
(p 0.006). There was no association between specific fungal genera
and mortality (Table 3).
Discussion
Despite recent reports of increasing incidence [1,4,12], infections
due to Mucorales remain infrequent. This multicentre study de-
scribes the epidemiology of mucormycosis across Australia,
demonstrating the diversity in causative fungi and predisposing
factors, and the overall high mortality despite intensive treatment
that included surgical debridement in most cases. Underlying
rheumatological/autoimmune disorders, haematological malignancy
and ICU admission were variables associated with increased
mortality.
Rhizopus spp. account for most cases of invasive mucormycosis,
with R. arrhizus (formerly R. oryzae) the predominant species
[1e3,5e7,19]. In this study, R. microsporus was most frequently
isolated although almost 40% of Rhizopus spp. were not assigned to
species level and hence certain species may have been under-
represented. Rhizopus microsporus has been associated with noso-
comial outbreaks [11]; however, we did not observe any case
clusters. Contrary to European studies where Lichtheimia spp. have
represented up to one-third of cases [2,3,6,20], this genus was
encountered infrequently. Of note, Apophysomyces spp. and Sakse-
naea vasiformis complex together caused 10.8% of cases compared
with <5% in Europe [2,3,6,20]. In India however, Apophysomyces
spp. is the second most common causative pathogen [12].
Both Apophysomyces and Saksenaea are soil saprophytes, with
IFD occurring mainly in tropical and subtropical climates [21]. As
noted by others [21], our eight patients were all
K.J. Kennedy et al. / Clinical Microbiology and Infection 22 (2016) 775e781780immunocompetent, had predominantly acquired infection through
trauma (75%) and had infection frequently localized to the skin/soft
tissue and bone/joint (50%). No infection involved the lung.
Excluding Apophysomyces and Saksenaea infections, the major-
ity of hosts were immunocompromised, most commonly haema-
tological malignancy and corticosteroid use. Indeed haematological
malignancy has surpassed diabetes mellitus as the commonest
predisposing factor in many regions [1e3,5] excluding countries,
such as India [12]. Although diabetes was present in 27% of our
patients, ketoacidosis was not observed [1].
A key finding from this study was the relatively high proportion
of patients with rheumatological/autoimmune conditions (12.1% of
cases) comparedwith previous studies (<2%) [1,2,22]. Such patients
may be at risk for IFD because of intensive immune suppression,
but have delayed diagnosis and institution of appropriate treat-
ment due to under-recognition of the risk. Importantly, outcomes
were particularly poor (100% mortality), indicating the need for
heightened awareness among clinicians of mucormycosis and
further research into risk profiles in this patient cohort.
Trauma, burns or surgery have been identified as risk factors for
mucormycosis in as many as 19% of cases [1e3,9,23] and typically in
immuno-competent hosts. Of the 17 trauma-associated cases in
this series, 9 (53%) had disseminated mucormycosis, which may
have contributed to the higher mortality (41%) than generally
observed (22.9%) [8]. As observed previously [9], mucormycosis
resulting from trauma was more commonly associated with non-
Rhizopus Mucorales (73.3%).
Improvements in laboratory techniques over time have resulted
in increases in the isolation rate of pathogenic Mucorales [1]. In this
series, 77% of cases were diagnosed by culture with/without his-
topathology. Although DNA sequencing of the cultured isolate or
directly from tissue (either fresh or retrieved specifically for this
study), provided species or genus identification in 35 episodes,
including five episodes diagnosed by histopathology alone, 9
Mucorales could not be assigned to a species. We used ITS
sequencing as a first-line method for species identification as is
recommended [24,25]. However, assays which target the ITS region
lack sufficient discriminatory power, particularly if direct detection
in tissue is attempted. Sequencing of alternate loci, such as the 18S
and 28S rRNA regions and cytochrome b may be additionally
required to speciate Mucorales [25]. Nonetheless, routine use of
molecular diagnostics has the potential to improve the identifica-
tion of Mucorales, particularly species such as Apophysomyces and
Saksenaea spp. that do not sporulate well.
Infection sites were similar to previous reports [1e5,19]
excluding higher occurrences of disseminated infection (39.2% vs
6.8e26%). All infections involving gastrointestinal tissue (9.5%)
were disseminated. Gastrointestinal mucormycosis is uncommon
and is predominantly associated with low-birthweight infants,
malnutrition and peritoneal dialysis [1]. These predisposing factors
were not noted in our study. Both patients with fungaemia had
Mucor spp. infections, with one surviving beyond 6 months [26].
Positive ante-mortem blood cultures in the context of mucormy-
cosis are extremely rare [27].
The 180-day mortality remains high (57%) despite antifungal
therapy with or without surgery, and is comparable to that re-
ported previously (44e59%) [1e3,5]. Despite the availability of
amphotericin in the 1960s, there has been no significant
improvement in mucormycosis-associated mortality [1]. However,
over this time there has been an increase in the proportion of cases
of mucormycosis in severely immuno-compromised individuals.
Indeed, in our study, the poorest outcomes were identified for the
first time in patients with rheumatological/autoimmune condi-
tions, with independent predictors of death also including under-
lying haematological malignancy and ICU admission. Conversely,survival was greatest in those without co-morbidities. Divergence
in survival between cases with and without haematological ma-
lignancy occurred approximately 1 month after diagnosis, sug-
gesting that persisting immuno-compromise is the key to poor
outcomes. This finding is important for the design of new clinical
trials, as assessment of clinical endpoints may need to be under-
taken at specific times in different populations.
Limitations of this study include its retrospective nature, which
may explain the relatively low numbers of probable episodes, and
trauma-related cases could be over-represented because tissue-
confirmed cases are easier to acquire. Potential differences in
clinical and diagnostic practice may have influenced case detection
and outcomes. In particular, as there was no systematic use of
molecular diagnostics, the diversity of Mucorales may have been
underestimated, affecting the reported relationship between spe-
cific genera and clinical features and outcomes. The study did not
capture all hospitals across Australia, hence the incidence of
infection cannot be accurately determined.
In conclusion, this study provides insights into mucormycosis
within Australia, and highlights the need for further research to
facilitate risk stratification, case definitions in immuno-competent
hosts, early diagnosis and optimal management to improve the
currently poor outcomes.
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